The intratumoral aromatase model: Studies with aromatase inhibitors and antiestrogens

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 283-288

  Brodie, Angela H ^a   Jelovac, Danijela ^a   Long, Brian ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antiestrogen; Aromatase; Tamoxifen

Indexed keywords

ANASTROZOLE; ANDROSTENEDIONE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FULVESTRANT; LETROZOLE; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER THERAPY; CELL GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARIECTOMY; SUPPLEMENTATION; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS; MUS MUSCULUS;

EID: 0242457702     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00368-6     Document Type: Conference Paper

References (22)

1. Hemsell D.L., Gordon J., Breuner P.F., Siiteri P.K. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J. Clin. Endocr. Metab. 38:1974;476-479.
2. van Landeghem A.A.et al. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45:1985;2900-2906.
3. A.S. Levenson, V.C. Jordan, Selective estrogen receptor modulation, in: J. Pasqualini (Ed.), Breast Cancer: Prognosis, Treatment and Prevention, Marcel Dekker, New York, 2002, pp. 271-280.
4. Brodie A.M., Schwarzel W.C., Shaikh A.A., Brodie H.J. The effect of an aromatase inhibitor, 4-hydroxy-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology. 100(6):1977;1684- 1695.
5. A. Brodie, Aromatase inhibitors and the application to the treatment of breast cancer, in: J. Pasqualini (Ed.), Breast Cancer: Prognosis, Treatment and Prevention, Marcel Dekker, New York, 2002, pp. 251-270.
6. Coombes R.C., Goss P., Dowsett M., Gazet J.C., Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 2(8414):1984;1237-1239.
7. Goss P.E., Coombes R.L., Powles T.J., Dowsett M., Brodie A.M.H. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res. 46(9):1986;4823-4826.
8. Yue W., Brodie A.M.H. A nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 54:1994;5092-5095.
9. Yue W., Wang J., Savinov A., Brodie A. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res. 55(14):1995;3073- 3077.
10. Zhou D., Pompon D., Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 50:1990;6949-6954.
11. Lu Q., Yue W., Wang J., Liu Y., Long B.J., Brodie A. The effect of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res. Treat. 50:1998;63-71.
12. Lu Q., Liu Y., Long B.J., Grigoryev D., Gimbel M., Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res. Treat. 57(2):1999;183-192.
13. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Lassus M., Verbeek J.A., Staffler B., Chaudri-Ross H.A., Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19(10):2001;2596-2606.
14. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J. Clin. Oncol. 18(22):2000;3748-3757.
15. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol. 18(22):2000;3758-3767.
16. Jones S., Vogel C., Arkhipov A., Fehrenbacher L., Eisenberg P., Cooper B., Honig S., Polli A., Whaley F., di Salle E., Tiffany J., Consonni A., Miller L. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J. Clin. Oncol. 17(11):1999;3418-3425.
17. Brodie A.et al. Aromatase inhibitors and their antitumor effects in model systems. Endocr. Relat. Cancer. 6(2):1999;205-210.
18. Long B.J., Jelovac D., Thiantanawat A., Brodie A.M. The effect of second-line antiestrogen therapy on breast tumor growth following first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin. Cancer Res. 8:2002;2378-2388.
19. B.J. Long, D. Jelovac, V. Handratta, A. Thiantanawat, N. MacPherson, J. Ragaz, A.M. Brodie, Evaluating the effects of sequential, combined, and alternating therapy with the aromatase inhibitor letrozole and the antiestrogen tamoxifen using a preclinical model of postmenopausal breast cancer, JNCI, in press.
20. Mouridsen H.T., Brodie A.H. Applicability of murine tumor models to predict clinical trial results with endocrine therapy. Am J. Clin. Oncol. (CCT). 26(4 Suppl. 1):2003;S17-S26.
21. The ATAC Trialists' Group, Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'arimidex and tamoxifen alone or in combination' (ATAC) trial, Br. J. Cancer 85 (3) (2001) 317-324.
22. Winer E.P., Hudis C., Bursein H.J., Chlebowski R.T., Ingle J.N., Edge S.B., Mamounas E.P., Gralow J., Goldstein L.J., Pritchard K.I., Braun S., Cobleigh M.A., Langer A.S., Perotti J., Powles T.J., Whelan T.J., Browman G.P. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol. 20:2002;3317-3327.